. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Appl Biochem Biotechnol. 2011 Sep 27;165(7-8):1628–1651. doi: 10.1007/s12010-011-9383-z

Table 1.

Summary of number of different cancer targeting and cancer therapy approaches using natural and synthetic polymeric nanoparticle formulation. Characteristics: Size, zeta potential, imaging agent, targeting agent.

Method	Polymer	Solvent	Stabilizer	Size (nm)	Drug	Surface Modification	Zeta Pot.	Imaging Agent	Multifunctional	Targeting	[ref]
SD	poly(anhydride)	Ac	-	140–180	Cyclodextrin		−50	N	N	N	[73]
2step desolvation	Gelatin	Ac	glutaraldehyde	250–300		NeutrAvidinanti-CD3 Ab	−20	N	N	Anti-CD3 antibody	[74]
ESE	PLGA	EA	DMAB	121	Paclitaxel		+35to+45	N	N	N	[67]
NP	PLGA	Ac	Stabilizer free	~156	Taxol	^**surface		^***NPQD	^*I/C/H, Fe₃O₄	N	[75]
SESD	PLGA	ACN	PVA	~150	Paclitaxel	PEG-QDs		QDs	^*I/C/H, Fe₃O₄	PSMA	[76]
NP/SD	PLGA	DMSO	Pluronic	104–144	N	heparin/chitosan	−20 to −50, +28	Cy5.5	I/C	N	[40]
CC	Chitosan	-	-	237	DNA	None	+15	N	N	N	[77]
NP	PEGb-PLGA	Ac	PEG	114–146	Paclitaxel	PEG	−~0	N	N	RGD peptide	[78]
NP	PLGA-PEG	Ac	PVA	~149	9nitrocampto thecin	PEG	+1.84	N	N	N	[79]
extrusion	Liposomes	N	PEG	100	DOX	PEG	NR	N	N	mAb 2C5	[80]
self- assembled	Glycol-Chitosan-PEI	-	-	100–300	siRNA		+9.95	Cy5.5	Imaging/gene silencing	-	[81]
EDE	PLGA	EA	PVA	~166	tamoxifen	N	~+3.5	N	N	N	[82]
EI	Chitosan-g-PEG	acetate buffer	-	~200	DNA	PEG	~+15	N	N	N	[83]
dialysis	Chitosan	-	-	~260	Paclitaxel	N	NR	Cy5.5	I/C	N	[84]
w/o/w ESE	PLGA	EA	PVA	320–360	BSA	N	−25	N	N	mAb	[85]
NP	PLGA	Ac	Pluronic	100–125	DOX	PEG	~−30	Au	^*I/C/H	N	[86]
NP	PLGA	Ac	-	~200	Docetaxel	PEG	~−26	N	N	HER-2	[87]
SESE	PLGA	MeOH/CHCl₃	PVA	~226	DOX	N	~−5	N	N	NLS	[88]
SD	PLA and PLGA	Ac	Tween-80	100, 200	Docetaxel		−28, −7	N	N	N	[89]
Comm.available	PIHCA	-	-	-	siRNA	chitosan	NR	N	N	N	[90]
co-precipitation	Chitosan	Water	N	10.5	Fe3O4 - hyperthermia	chitosan	N	-	Fe₃O₄	N	[91]
MESE	PLGA	DCM	PVA	276–550	tamoxifen	N	NR	N	N	N	[92]
SESD	PLGA	MeOH/ ACN	PVA	~300	N	N	−16.3	ICG	N	N	[93]
w/o/w ESE	PLGA	DCM/AC	PVA	~436	DOX, pEGFP DNA	PEG-Liposome	+30.9		Chemo/gene delivery	Folate	[94]
CC	Chitosan	acetate buffer	-	~181	DOX, DNA.	-	NR	N	Chemo/gene delivery	Folate	[95]
IG	Chitosan	Water	gluteraldehyde	~187	methotrexate	N	+30	N	N	N	[96]
NP	PLGA	Ac	PVA	~76.2	curcumin	N	~0	N	N	N	[97]

Abbreviations: ESE=emulsion solvent evaporation, EDE =emulsion diffusion evaporation, SESE =single emulsion solvent evaporation, SD =solvent displacement, MESE =multiple emulsification (w/o/w) and solvent evaporation, SESD =spontaneous emulsion solvent diffusion, EI =electrostatic interaction, CC =complex coacervation, NP =nanoprecipitation, IG =ionic-gelation, PIHCA =polyisohexylcynoacrylate, EA = ethyl acetate, MeOH/ACN = methano/acetonitrile, DCM/AC =dichloromethane/acetone, DMSO =dimethylsulfoxide, Ac =acetone, PVA =polyvinylalcohol, PEG = polyethyleneglycol, QDs =quantum dots, N =none, NR =not reported

I/C =Imaging/Chemotherapy,

I/C/H =Imaging/chemotherapy/hyperthermia,

^**

surface = NH2-terminal Fe3O4 and NH2-PEG-QDs,

^***

NPQD =NH2-PEG-QDs